Evidence map›Paper›PMID 42856505›Full record

ArticlebioRxiv : the preprint server for biology2026

Pan-Coronavirus Protease Engagement and Differentiated Pharmacology of Antiviral Candidate CMX990.

N G R Dayan Elshan, Karen C Wolff, Laura Riva, Malina A Bakowski, Simeon Babarinde, Anshul Chaudhary, Mark Zeller, Ashley K Woods, Gennadii Grabovyi, Katy B Wilson and 32 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

N G R Dayan ElshanCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7830-1477
Karen C WolffCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Laura RivaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-2414-7341
Malina A BakowskiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-3337-6528
Simeon BabarindeDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-5603-4769
Anshul ChaudharyDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Mark ZellerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Ashley K WoodsCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Gennadii GrabovyiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-8999-9532
Katy B WilsonCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Rebecca A LeonardDepartment of Microbiology and Molecular Genetics, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-3404-0399
Briana L McGovernDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jared BenjaminDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Isidora SuazoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mary GordonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Frank O WeissCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Sourav GhoraiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-8093-5655
James R PedroarenaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0009-0006-0742-9784
Kristi L MarquardtDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Maheeka BimalDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Stuart WestonDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Carly DillenDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Appaso M JadhavCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Melanie G KirkpatrickCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Amal Gebara-LambCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0009-0003-2271-3116
Nisar FarhatCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Vân T B Nguyen-TranCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Victor ChiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Kyoung-Jin LeeCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Case W McNamaraCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-5754-3407
Anil Kumar GuptaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-5035-9597
Alireza RahimiCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
John R TeijaroDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jian Jeffrey ChenCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-3847-8117
Sean B JosephCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-2602-8517
Matthew FriemanDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Nicholas S HeatonDepartment of Microbiology and Molecular Genetics, Duke University School of Medicine, Durham, North Carolina, USA.
Kris WhiteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-6469-2419
Peter G SchultzCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-3188-1202
Sumit K ChandaCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.
Arnab K ChatterjeeCalibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-5171-7982

Funding

Targeting druggable coronavirus proteinsU19AI171443 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Arnab Kumar Chatterjee · 2022 to 2026
$101.4M
Bill & Melinda Gates Foundation INV-028691NIAID NIH HHS U19 AI171443
6 · The paper itself

Abstract

COVID-19 highlighted the need for antivirals that can be rapidly deployed against both current and future coronavirus threats. CMX990 is a clinical stage coronavirus main protease (M

Indexed as

3CLproCMX990coronavirusMpropeptidomimeticresistanceSARS-CoV-2

Identifiers

PMID42856505
PMCPMC13648650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.